Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 4

New developments in the treatment of HER2-positive breast cancer

Authors Nahta R

Received 9 March 2012

Accepted for publication 16 March 2012

Published 7 May 2012 Volume 2012:4 Pages 53—64


Review by Single-blind

Peer reviewer comments 2

Rita Nahta

Departments of Pharmacology and Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA

Abstract: Approximately 20%–30% of metastatic breast cancers show increased expression of the human epidermal growth factor receptor-2 (HER2) tyrosine kinase. Two HER2-specific therapies are currently approved for clinical treatment of patients with HER2-overexpressing metastatic breast cancer. Trastuzumab is a monoclonal antibody against HER2 and is approved for first-line treatment of HER2-positive metastatic breast cancer. Lapatinib is a small molecule dual inhibitor of epidermal growth factor receptor and HER2 tyrosine kinases, and is approved for trastuzumab-refractory disease. Although trastuzumab is a highly effective therapy for patients with HER2-overexpressing metastatic breast cancer, a significant number of patients in the initial clinical trials of trastuzumab monotherapy showed resistance to trastuzumab-based therapy. Further, among those who did respond, the initial trials indicated that the median time to progression was less than 1 year. Similarly, lapatinib is effective in a subset of trastuzumab-refractory cases, but the majority of patients display resistance. This review discusses the multiple molecular mechanisms of resistance that have been proposed in the literature. In addition, novel agents that are being tested for efficacy against HER2-positive breast cancer, including the antibodies pertuzumab and trastuzumab-DM1 and the immunotoxin affitoxin, are reviewed. The introduction of trastuzumab has revolutionized the clinical care of patients with HER2-positive metastatic breast cancer and has resulted in dramatic reductions in recurrences of early-stage HER2-positive breast cancer. The development and implementation of gene- and protein-based assays that measure potential molecular predictors of trastuzumab resistance will allow individualization of HER2-targeted therapeutic approaches, and may ultimately improve treatment of HER2-positive breast cancer.

Keywords: ErbB2, Herceptin, trastuzumab, drug resistance, neratinib, lapatinib, affitoxin

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study

Niu NK, Yin JJ, Yang YX, Wang ZL, Zhou ZW, He ZX, Chen XW, Zhang XJ, Duan W, Yang TX, Zhou SF

Drug Design, Development and Therapy 2015, 9:4441-4470

Published Date: 7 August 2015

Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen

Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2014, 8:1307-1314

Published Date: 9 September 2014

Developing a bone mineral density test result letter to send to patients: a mixed-methods study

Edmonds SW, Solimeo SL, Lu X, Roblin DW, Saag KG, Cram P

Patient Preference and Adherence 2014, 8:827-841

Published Date: 5 June 2014

Spatial memory impairments in amnestic mild cognitive impairment in a virtual radial arm maze

Lee JY, Kho S, Yoo HB, Park S, Choi JS, Kwon JS, Cha KR, Jung HY

Neuropsychiatric Disease and Treatment 2014, 10:653-660

Published Date: 17 April 2014

Predictors of repeated sick leave in the workplace because of mental disorders

Sado M, Shirahase J, Yoshimura K, Miura Y, Yamamoto K, Tabuchi H, Kato M, Mimura M

Neuropsychiatric Disease and Treatment 2014, 10:193-200

Published Date: 29 January 2014

Non-adherence to topical treatments for actinic keratosis

Shergill B, Zokaie S, Carr AJ

Patient Preference and Adherence 2014, 8:35-41

Published Date: 17 December 2013

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010